Method of producing peptides

专利摘要:
Human GRF(hGRF), rat GRF(rGRF), porcine GRF(pGRF) and bovine GRF(bGRF) have been earlier characterized and synthetized. The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans, which have resistance to enzymatic degradation in the body, and which have the sequence: R1-R2-R3-Ala-Ile-Phe-Thr-R8-Ser-R10-Arg-R12-R13-R14-R15-Gln-R17-R18-Al a-Arg-Lys-Le u-R23-R24-R25-Ile-R27-R28-R29-Gln-Gln-Gly-Glu-R34-Asn-Gln-Glu-R38-R39- R40-Arg-R42- R43-R44 wherein R1 is Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Lou, His or D-His having either a C< alpha >Me or N< alpha >Me substitution or being unsubstituted; R2 is Ala, D-Ala or D-NMA; R3 is Asp or D-Asp; R8 is Ser, Asn, D-Ser or D-Asn; R10 is Tyr or D-Tyr; R12 is Arg or Lys; R13 is Ile or Val; R14 is Leu or D-Leu; R15 is Gly or D-Ala; R17 is Leu or D-Leu; R18 is Tyr or Ser; R23 is Leu or D-Leu; R24 is His or Gln; R25 is Glu, Asp, D-Glu or D-Asp; R27 is Met, D-Met, Ala, Nle, Ile, Leu, Nva or Val; R28 is Asn or Ser; R29 is Arg or D-Arg; R34 is Arg or Ser; R34 is Gln or Arg; R39 is Arg or Gly; R40 is Ser or Ala; R42 is Phe, Ala or Val; R43 is Asn or Arg; R44 is a natural amino acid; provided however that any or all of the residues between R28 and R44, inclusive, may be deleted and provided also that R2 is D-NMA and/or R14 is D-Leu and/or R29 in is D-Arg. Those peptides as well as their nontoxic salts may also be used diagnostically.
公开号:SU1530097A3
申请号:SU853898058
申请日:1985-05-17
公开日:1989-12-15
发明作者:Уолкер Вейл Вили (Младший)；Эдуард Фредерик Ривье Жан
申请人:Дзе Салк Институт Фор Биолоджикал Стадиз (Фирма)；
IPC主号:

专利说明:

The invention relates to a method for producing peptides, new biologically active compounds that can be used in medicine.
The purpose of the invention is a method for producing new compounds in a number of peptides that are low-toxic and are more effective in stimulating the release of growth hormone by the pituitary gland.
Example 1. Synthesis of D-NMA peptide, -gSKG (1-29) -Sh2 having the following formula: H-His-D--NMA-Asp-Ala-Ile-Phe-Thr-Ser-Ser--Tyr-Arg- Arg-Ile-Leu-Oly-Gln-Leu-Tyr-Ala-Arg-Lys-Leu-Leu-His-Glu-Ile-Nle-Asn-Arg-mi7A is performed sequentially using a Beckmann 990 peptide synthesizer on an MBHA resin. have a substitution interval of about 0.1-0.5 mmol / g resin. The binding of Boc-ArgCToS) to the resin is carried out in the usual way using a mixture of methylene chloride and DMF at a temperature of about 60 ° C for 2 hours with stirring using 2 g of resin and 2 mmol of Arg and a replacement of about 0.35 mmol of Arg is obtained by 1 g resin.
After release and neutralization, the peptide bond is gradually formed on the resin. The release, neutralization and addition of each amino acid is carried out in the usual way. All solvent applicants are thoroughly degassed by purging with an inert gas, such as helium or nitrogen.
The release is preferably carried out according to mode A:
ReagentTime with 60 TFA 11% ethanedithiol 60% TFA / 2% Ethanedithiol IPA ztandithiol (10%) in Me OH
Et, N (10%) in MeOH (twice) (twice)


Combinations preferred according to mode B
Reagent
DCC1 all - amino acid
Meon (twice) (twice) (3M) in
0.5 0.5 15.0 0.5
MeOH0.5
 (twice) 0.5
In general, from 1 to 2 mmol of an amino acid protected by BFB (tert-butoxycarbonyl) in methylene chloride, DMF, or a mixture of them, is applied to 1 g of resin plus one equivalent of 1.0 mol DCC1 (S, y-dicyclohexylcarbodiimide) in chloride methylene for 2 hours
In combination with BOC-Arg (ToS), a mixture of 50DMF (dimethylformamide) and methylene chloride is used. PZI ester is used as a side-chain hydroxyl protecting group to protect 8g (serine)
Q and Thr (threonine). Amidogroup Avp
(asparagine) or Gin (glutamine) is protected by xanthyl (Hap) when the preferred DCC bond is used (M, n is dicyclohexylcarbodiimide). Can
5 also apply p-nitrophenyl
an ester (ONp) to activate the terminal carboxyl group of Asn or Gin and, for example, BOC-Asn (ONp) can be bound overnight using one equivalent of HOBt in a mixture of dimethylformamide (DHF) and methylene chloride, in which case DCC is not add. For the protection of Lys (lysine) with a side chain, 2-chloro-benzyloxycarbon-14L- (2C1-Z) TO8 is used.
5 is used to protect the guanidine group Arg and the imidazole nitrogen His, the carboxyl group in the side chain of Gin or Asp protect OBZ1. The phenolic hydroxyl group is protected by 2,6-di0 chlorobenzyl (DCB). At the end of the synthesis, the following composition is obtained: Bpc-His-D- -NMA-Asp (X3) -Ala-Ile-Phe-Thr (X4) - -Ser (XO-Ser (X) -Tyr (Xg) - Arg (Xy) - Arg (Xj) -lle-Leu-Gly-Gln (X) -Leu5 -Tur (XT) -Ala-Arg (Xe) -Lys (Xj) -Leu-Leu- -His-Gln ( Xj) -Ile-Nle-A8n (Xf) -Arg (X) - MBHA, where X is DCB (2.6 where Xj is DCB (2,6-dichlorobenzene), X, is OBZl;
0 X, - BZ (dibenzyl ether), Xg- - Xan, Hb - ToS; X7 - 2C1-Z.
5 Xan (xanthyl) can be partially or completely removed by treatment with TFA used to unlock the α-amino acid protection group.
51
To separate and deprotect the protected peptide on the resin, it is treated with 1.5 ml of anisole, 0.5 ml of methyl ethyl sulfide and 15 ml of hydrogen fluoride per gram of peptide-resin at 0 ° C for 30 minutes. After removing the hydrogen fluoride under high vacuum conditions, the residue from the resin and the peptide is alternately washed with dry diethyl ether and chloroform, and then the peptide is recovered using degassed 2N. aqueous acetic acid and separated from the resin by filtration.
Thereafter, the separated, deprotected peptide is dissolved in 0-5% acetic acid and purified, which may include fine filtration through a Sephadex G-50 gel.
Then the peptide is further processed by preparative or semi-preparative HPLC. Cartridges equipped with Water-Lssocity's LC-500 composition are filled with 15–20 mg of silica C from Vydac (ZOOL). The CHjCN gradient in TEAR is created by the Eldex gradient maker low pressure device. Chromatographic fractions are carefully controlled by HPLC, with only fractions showing significant purity being collected; The desalting of the purified fractions, separately carried out for purity, is achieved by applying an OO gradient of .1% TPA (trifluoroacetic acid). Then, the excised center is lyophilized to obtain the desired pegTtide with a purity greater than 98.
7.2 mg of peptide having an amidated C-chain end are obtained in a yield of about 5% of the amount of the peptide cleaved.
PRI mme R 2. Synthesis of peptide ID-NMA, ser, ine-gskg (1-29) -Shg,
having the formula: H-His-DN IA-Asp-Ala-Il-Phe-Thr-Ser-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-T, eu-Ser-Ala-Arg-Lys- Leu-Leu-His-Gln-Ile-tlle-Asn-Arg-MH is carried out gradually in a Beckmann 990 synthesizer on an MBHA resin, analogously to Example 1. A very pure peptide is obtained using TLC with HPLC.
PRI me R 3. Synthesis of hGRF-- analog fragment .D-№1A, -hGRF (1-29) - ™ 2., Having the formula: H-Tyr-D-miA-Asp-Ala-Ile-Phe -Thr-Asn-Ser-Tvr-Arg-Lys-Val-Leu-Gly-Gl n-Leu
15
300976
-Ser-Ala-Arg-Ly s-I, eij-J, eu-Cln-Asp-lI e -Nle-Ser-Arg-mia
is carried out gradually in a synthesizer for peptides of the Beckman type 990 on the MVNA resin according to example 2
Using TLC (thin layer chromatography) and HPLC, it is determined that a substantially pure peptide is obtained. Q Examples Synthesis of part of the analog hGRF b-NMA, Nle, D-Arg J - SGG.G
(1-29) -KHt. which has the formula: H-Tyr-D-NMA-Asp-Ald-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-C-ly-Gln-Leu--Ser-Ala-Arg- Lys-Leu-Leu-Gln-Asp- -Ile-Nle-Ser-D-Arg-m; sequentially in a Beckman 990 synthesizer for peptide synthesis on ShHA resin as in example 1,
2Q When using 1C and HPLC, an almost pure peptide is obtained.
PRI me R 5. Synthesis D-Leu, Nle J-rGRF (1-29) -Wl2, having the formula:
25 H-His-AIa-Asp-Ala-Ile-Phe-Thr-Ser-Ser-Tyr-Arg-Arg-Ile-D-Leu-Cly-Gln--Leu-tyr-Ala-Arg-Lys-Leu -Leu-His-Gln-Ile-Nle-Asn-Arg-m 2 is carried out sequentially in a Beckman 990 synthesizer for the synthesis of peptides on MBHA resin, as in Example 1. Using TLC and HPLC, an almost pure peptide is obtained.
PRI me R 6. Synthesis of P-GO1A, Asn J-hGRF- (1-29) -mig, which has the formula:
H-Tyr-D-NMA-Asp-Ala-Ile Phe-Thr- -Asn-Ser-Tyr-Arg-Lys-Val-Leu-} ly Gln- -Leu-Ser-Ala-Arg-Lys-Leu-Leu -Gln-Asp- -II e-Nle-Asn-Arg-IIHj
thirty
40
conducted sequentially in peptide
Beckman 990 synthesizer on MBNA resin, as in Example 1. The peptide was evaluated as practically pure, using TLC and HPLC.
Example7. Synthesis of fNle, D-Arg 2j -rGPJ (1-29) -HH2, having the formula:
H-His-Ala-Asp-Ala-Ile-Phe-Tbr-Ser-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-Lys-Leu-Leu-His The -Gln-Ile- -Nle-sn-D-Arg-NH2 is carried out gradually in a Beckman 990 synthesizer on an SHHA resin, as in Example 1. According to TLC and HPLC, a substantially pure peptide is obtained.
PRI me R 8. Synthesis of analog hGRF fragment fn-roiA, D-Tyr °, Nle-hGRF (1-29), having the formula:
H-Tyr-D-ri A-Asp-Ala-Ile-Phe-Thr-As-Ser-D-Tyr-Arg-Lys-VAl-Leu-Gly-Gln-Leu-Ser-Ala-Arp, - Ly8-Leu-Leu-Gln- -Asp-Ile-Nle-Ser-Arg-mij
is carried out gradually in a Beckman 990 synthesizer on an SHA resin, as in Example 1. When TLC and HPLC are used, mostly pure peptide is obtained.
Froze Synthesis of analog hCRF fragment / JD-NMA .Nle U-hCRT (l-29) -NHEt, having the following formula:
H-Tyr-D-IJMA-Asp-Ala-lle-Phe-Thr-As-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln--Leu-Ser-Ala-Arg-Lys-Leu- Leu-Gln-Asp-α-Ile-Nle-Ser-Arg-iraCHjCH is performed sequentially in a Beckman 990 peptide synthesizer on an N-alkylamine resin, also called N-ethylaminomethyl resin (NEAM resin). Approximately 10 g of 1 crosslinked chloromethylated polystyrene resin is reacted with 50 ml of ethylamine at a temperature of about k C for approximately 36 hours with continuous stirring to replace the chlorobenzyl groups with N-ethyl aminobenzyl groups and after completion of the reaction several times - washed with methanol and water. Then, a peptide is synthesized on the initial substituted amide bond. After obtaining the desired reptile sequence, the protection is removed and the resin is cleaved by treatment with hydrofluoric acid with anisole as an acceptor, the wire is first stirred, at 0 ° C, and then left the mixture to slowly warm with stirring to room temperature for about 3 hours. wherein the peptide is cleaved from the resin as ethylamide. According to TLC and HPLC, an almost pure peptide is obtained.
I'll try it on. Synthesis of D-NMA, Nle, (1-29) -miEt having the following formula:
H-Tyr-D-tlMA-Asp-Ala-Ile-Phe-Thr-As-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu -Gln-Asp -Ile-Nle-Asn-Arg-ITHGH Ql is carried out sequentially using a Beckman 990 peptide synthesizer on a MEAM resin in analogy to Example 9. According to TLC and HPLG, this analog peptide is practically pure.
0
5 5 Q
:)
0 5
five
0
PRI me R 1 1.
Synthesis of analogue liGRF fragment His, D-NMA2, -hGRF (l-29) -NH having the following formula:
H-His-D-NMA-Asp-Ala-Ile-Phe-Thr-As-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln- -Leu-Ser-Ala-Arp.-I.ys -Leu-Leu-Gln-Asp-Ile-Nle-Ser-Arg-IIH
performed sequentially using the Beckmann 990 peptide synthesizer on the ShNA resin as in Example 1. According to the TLG and HPLG data, the peptide is almost pure.
The results of the analysis are shown in the table.
Biological testing of the synthetic peptides prepared in the examples was carried out.
For comparison, artificial human growth hormone secretion factor was used. In vitro experiments have found that peptides obtained under the conditions of the proposed method have a generally greater capacity for secreting growth hormone (GH) and similar inherent activities. All of these artificial peptides are considered biologically active and potentially useful for stimulating growth hormone secretion through the pituitary gland.
When conducting tests, cultures were used that included rat pituitary cells removed 3-5 days ago.
Such cultures are considered optimal for secreting growth hormone and are used in comparative tests carried out according to Weil's method. The incubation period for the test substance was W-h. The cultured medium lliquots were removed and processed to measure their content in the immunoreactive growth hormone GH (ir GH) using radio immunology.
The results of the comparative test for equimomeric concentrations are shown in the table.
In vitro tests of artificial peptides show that many of them have higher biological power than, for example (in the part of the brain under the visual bump) hpGRF (1- &gt; 0) -OH: the minimum effective concentration, D-isomer of alanine, norm - The leucine-human hGRF (1-29) amino group is about 1 mmol.
In addition to in vitro growth hormone secretion tests, artificial peptides were injected intravenously into rats with anesthesia (with urethane). At the same time, 1; quick peptides suppressed spontaneous secretion of growth hormone without killing the response to an external growth factor release factor (GH). Before injection, after 10 , 30 and 90 min took a blood test. The levels of growth hormone (SI) in the blood, measured by test-tube radioimmunology,
showed that artificial Gl-iso5 - 27 t
alanine measures, norleicin J-human hGRF (1-29) -Mil J is about 6 times stronger than human hGRF (1-jO) pH in terms of blood levels of growth hormone secreted by the pituitary gland, as measured after 10 and 30 minutes after injection. To confirm these results, other known in vitro growth hormone secretion factor (GRF) trials have been used that are effective in determining growth hormone secretion. Doses of about 50 ng and about 5 mg of these peptides per kg of body weight are considered effective to induce growth hormone secretion.
Some peptides, which have equal or even slightly lower biological power in in vitro tests than the standard, have significantly greater power in life.
Such artificial analogs of human hGRF and rat GRT, bovine and piglet analogs (in upGRF)
R -Rj-Asp-Ala-Ile-Phe-Thr-R-Ser-Arp-R, 4.-R, 5-Ri4 C-ly-Gln-Leu-R 8 - -Ala-Arg-Lys-Leu -Leu-R -R jR -Nle- 49 Y,
His;
DOTIA;
where R is Tyir, R is Ala.
ten
15
Rg - Ser, Asn;
 Tyr, DTyr;
R, i -Arg, Lys;
R ,, - lie, Val; R, - DLeu, Leu ;.
Rie-Tyr, Ser;
Rg-His, Gin;
Rjj - Gin, Asp; 26 - lie;
R-jg - Asn, Ser;
20
25
thirty
 28
Rja -Arg, DArg; Y- - NH, provided that either RZ DOTIA,
or R - DLeu, or - DArg,
characterized in that Baugh Arg (Tos) or Baugh D Arg (tos) is bound to NBNA or NEDM polymer resin, the Boc-protective group is cleaved and then a peptide chain is built, gradually adding the amino acid in the sequence due to formula I, obtained with this peptidyl polymer of general formula II
X, -R, (X or X) -Rz.,) -Ala- -Ile-Phe-Thr (X) -Rg- (X4. Or Xj -) - -Ser (X4) (Xj) -Arg (X6 -Ri (Xg or X7) -R ,, -R, 4-Gly-Gln (X5 -) - Leum can be categorized as little - 35 (X) -Ala-Arg (X6,) - Lys (X7) - Leu-Leu-R24 (X or Xj)) Ile-Nle-R2g (X or X5.) - R29 (X6) -Xg, where X is tosil, X, Boe; Y is 2,6-dichlorobenzyl,
toxic compound.
Thus, the biological tests performed showed that the peptides obtained under the conditions of the proposed method are of low toxicity and are more effective in stimulating the secretion of growth hormone by the pituitary gland in comparison with the synthetic human release factor for growth hormone hGRF () OH. In addition, the peptides obtained by this method have a shorter chain (29 amino acid residues), which greatly simplifies their preparation.
Formula
acquisitions
The method of half-peptides of the general formula I
R -Rj-Asp-Ala-Ile-Phe-Thr-R-Ser-Arp-R, 4.-R, 5-Ri4 C-ly-Gln-Leu-R 8 - -Ala-Arg-Lys-Leu -Leu-R -R jR -Nle- 49 Y,
His;
DOTIA;
where R is Tyir, R is Ala.
0
five
Rg - Ser, Asn;
 Tyr, DTyr;
R, i -Arg, Lys;
R ,, - lie, Val; R, - DLeu, Leu ;.
Rie-Tyr, Ser;
Rg-His, Gin;
Rjj - Gin, Asp; 26 - lie;
R-jg - Asn, Ser;
0
five
0
 28
Rja -Arg, DArg; Y- - NH, provided that either RZ DOTIA,
or R - DLeu, or - DArg,
characterized in that Baugh Arg (Tos) or Baugh D Arg (tos) is bound to NBNA or NEDM polymer resin, the Boc-protective group is cleaved and then a peptide chain is built, gradually adding amino acids in the sequence due to formula I, obtained with this peptidyl polymer of general formula II
X, -R, (X or X) -Rz.,) -Ala- -Ile-Phe-Thr (X) -Rg- (X4. Or Xj -) - -Ser (X4) (Xj) -Arg (X6 -Ri (Xg or X7) -R ,, -R, 4-Gly-Gln (X5 -) - Leu5 (X) -Ala-Arg (X6,) - Lys (X7) -Leu-Leu-R g ( X) -Ala-Arg (X6,) - Lys (X7) -Leu-Leu
-R24 (X or Xj)) Ile-Nle-R2g (X or X5.) - R29 (X6) -Xg, where X is tosyl, X, Boe; Y is 2,6-dichlorobenzyl,
Obz1
benzyl ether
xanthyl
tosil,
2-C1-benzyloxycarbonyl,
HVNA or NEAJ carrier resin, is unblocked and the peptide is uncoupled from the carrier resin and / or using hydrogen fluoride in combination with anisole or methyl ethyl sulfide or their mixture as an acceptor at a temperature from 0 to -20 ° C, the resulting product is are boiled in acetic acid and purified.
X. - X4
hG
XT X-

权利要求:
Claims (1)
[1]
Claim
The method of producing peptides of General formula I
R <-Rj, -Asp-Ala-Ile-Phe-Thr-Fg-Ser — Rjq —Arg — R —R. —R — C-ly — Gin — Leu — R ₄ g — -Ala-Arg-Lys-Leu-Leu-R ^ ₄ -R _i5 -P ^ -Nle
Y - Tyr, His; Ala, DNMA; ^R 3 - Ser, Asn; ^R io - Tyr, DTyr; R * i - Arg, Lys; ^R 13 - He, Vai; R _K - DLeu, Leu ;. ^R w - Tyr, Ser; r ₂₄ - His, Gin; R ₂₅ - Gin, Asp; ^R 26 " lie; ^R 28 ~ Asn, Ser; ^R 29 Arg, DArg; y - NH, NHC ^ Hy
provided that either R ₂ is DN1IA or DLeu or R ₂₉ DArg, characterized in that Boc Arg (Tos) or Boc D Arg (Tos) are bonded to the MBNA or NEDM polymer resin, the Boc protecting group is cleaved and then build a peptide chain, gradually adding amino acid residues in the sequence due to formula I, the resulting peptidyl polymer of General formula II X ₄ ~ R ₄ (X or X _g ) -R ^ -AspiX,) - Ala-Ile-Phe-Thr (X ₄ ) -Rg- (X ₄ or X ^) - Ser (X ₄ ) -R _<0 (X ₂ ) -Arg (X ₆ ) -R ₁ (Xg or X _T ) -R _n -R ₁₄ -Gly-Gln (X.5 -) - Leu-R _ift (X ₂ ) -Ala-Arg (X _& ) -Lys (X ₇ ) -Leu-Leu- R ₂₄ (X or X ^ - ^ iX ^ -Ile-nie-RjgCX ,. or X ) -R ₂₉ (X ₆ ) -X ₉ , where X is tosyl,
X ₄ = Vos;
X ^ - 2,6-dichlorobenzyl, x _e - OBZ1,
X ₄ is benzyl ether, Χ ₅ is xanthyl, Χ ₆ is tosyl,
Χγ - 2-C1-benzyloxycarbonyl, X < - carrier resin носΓΙ or MEAl · !, release and cleave the peptide from the carrier resin and / or using hydrogen fluoride in combination with anisole or methyl ethyl sulfide or a mixture thereof as an acceptor at a temperature of from 0 to -20 ° C, obtained the product is dissolved in acetic acid and purified.
I I
I I
I I
I I
I
I I t
I I
I I
I I I
I
I
I I
L
I
I I
I
I
I I
I I
I
X f S and f with X"to X > x q J 3 X about X b
b- -eleven1 s10) -1111 with  from1 f eleven 1- | n I fi X 1 q •to 1 X t about q 1 about 1 x X 1 1 o n 1 ί *1 1 <01 • q1 1 About and 1 1 x1 1 o1
I I
Ι- 1 Ο f 1 q x f 1 o q X 1 x f o) f 1 X X Μ * 1 ο φ about a 1 ί q o 1 x> x x y 1 X 3 O. 3 1 <. X with a> 1
L
eleven1 and 11 1 o Xabout ί qX X 1 s fq | AG1 1f 1 f Oh ~ έ ό’Ρabout. 1 x C | _1 g- f L 1 x X 1 f X xand * 1 n 1- X> » F ί f About ΣΓ II f N ί a Oh fwell about 1 s * with about > » q • 1 1 1 4 f1 f - q 31 x Oh f X1 x Oh b I1 f H x f1 b X x q <> ₽ ί s with co 1 s f F1 and x a 3I i *. X X
I
J
I
I
I
I t
I
I
I
СО 00 silt g ** (4 о
TS 40 sch or eaten with
G * - · h0 il
I or I
MF
SL G ** CN CM
Black or white
Midrange
Ghol * - OLSCH40G ** <L Gh «- J- ΠΊ g- - ooo o o oe oo oo oo oo oo nl (C il
CL or SCH
CL yl (XI (XI il pl pl yl cq (XI pl (XI (XI yl * - * - pl g * <* l count or so oo o
I
I I
I.
I
1 I
I
I I I
1 t
I I I I
I I
I I
I I
I I
I I
I I I
I
Midrange or LT5
I
MF 40 40 sludge
ABOUT about about about about about che about about about about oh oh oh oh about about about • about ate silt pl Midrange mid 00 about oo h0 PL 40 OL 40 G— "a- mid 1 with "- g— silt · - g * l ol mid siltmid mid silt * - 00 1
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II !!
I cii
I xi
I I-I
I ci
I 0) I
I czi
II
II tI
II
I1
II
-FROM
I o and u x: x
IX ate cd eat
Fss
X C O l x X <
fj frJ <l <M1 IN*-41 1>> M 1 N S EL to OL £ s 4J 1 eleven b mid eleven AND E! / * h g ~ x to 1 JE / 4 w £ ί t eaten eaten about * - Y eateneleven Z-4 mid sch l1 midrange 1 1
Zc about
M b ^r4
O Z P
I
• Ή O> -! * - * cm | g midnight Ui t- <Q *> f S * cm and T — 1 and a) n f g * - <* and 55 <} r— < 1 »“ <| J-4 At Z * 1 Z Q 55 Q 5l Th * m- Q ** * Eh 1 · - * - cm g ⁴ m -I e. cm - FL * G * Q

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1530097A3|1989-12-15|Method of producing peptides

---

SU1426455A3|1988-09-23|Method of producing peptides

---

SU1435157A3|1988-10-30|Method of producing peptides

---

SU1575944A3|1990-06-30|Method of obtaining peptides

---

SU1651787A3|1991-05-23|Method for preparation of polypeptide with properties of factor release of growth hormone

---

IE882185L|1989-01-17|Lhrh antagonists

---

US4562175A|1985-12-31|Synthetic peptides

---

SU1477248A3|1989-04-30|Method of producing peptides

---

AU598507B2|1990-06-28|Peptides with vasorelaxant, natriuretic and diuretic effects, a process for their preparation, agents containing them, and their use

---

WO1992000095A1|1992-01-09|Histidine substituted growth hormone releasing factor analogs

---

GB2184729A|1987-07-01|Calcitonin derivatives

---

SU1598881A3|1990-10-07|Method of producing peptides

---

EP0352014A2|1990-01-24|Cyclic GRF analogs

---

AU757222B2|2003-02-06|Antagonistic analogs of GH-RH inhibiting IGF-I and -II

---

US4687839A|1987-08-18|Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents

---

US4098777A|1978-07-04|Process for the preparation of pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn

---

SU1423000A3|1988-09-07|Method of producing peptides

---

US4774319A|1988-09-27|Synthesis of a derivative of GRF and intermediate peptides

---

CA1304193C|1992-06-23|Grf analogs v

---

AU593973B2|1990-02-22|Grf analogs v

---

IE64494B1|1995-08-09|Cyclic grf-analogs

---

König et al.1986|New analogues of secretin

---

JP3931194B2|2007-06-13|Analogs of thymosin α1

---

CA1304192C|1992-06-23|Grf analogs vi

---

US4407745A|1983-10-04|Heptacosapeptide

同族专利:

---

公开号 | 公开日

---

ES543235A0|1986-04-01|

---

DK162103B|1991-09-16|

---

FI851842L|1985-11-19|

---

CA1271299A|1990-07-03|

---

IE57813B1|1993-04-21|

---

KR850008681A|1985-12-21|

---

DE3585634D1|1992-04-23|

---

HUT37633A|1986-01-23|

---

US4528190A|1985-07-09|

---

IL75088D0|1985-09-29|

---

IL75088A|1988-12-30|

---

ES8606412A1|1986-04-01|

---

EG17394A|1992-12-30|

---

EP0161852A3|1988-10-26|

---

JPH0689036B2|1994-11-09|

---

PT80450B|1987-08-19|

---

NO851947L|1985-11-19|

---

AU578467B2|1988-10-27|

---

AT73823T|1992-04-15|

---

IE851087L|1985-11-18|

---

PT80450A|1985-06-01|

---

JPS60260595A|1985-12-23|

---

KR910000379B1|1991-01-24|

---

EP0161852A2|1985-11-21|

---

NO168043B|1991-09-30|

---

DK220685D0|1985-05-17|

---

FI851842A0|1985-05-09|

---

DK220685A|1985-11-19|

---

AU4248885A|1985-11-21|

---

HU197759B|1989-05-29|

---

EP0161852B1|1992-03-18|

---

MX157381A|1988-11-18|

---

FI92210B|1994-06-30|

---

YU46153B|1993-05-28|

---

NZ212113A|1988-05-30|

---

FI92210C|1994-10-10|

---

PH20976A|1987-06-15|

---

YU77185A|1988-04-30|

---

GR851207B|1985-11-25|

---

NO168043C|1992-01-08|

---

DD236536A5|1986-06-11|

---

ZA852919B|1986-11-26|

---

DK162103C|1992-02-17|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4563352A|1982-10-04|1986-01-07|The Salk Institute For Biological Studies|Human pancreatic GRF|

---

US4518586A|1983-01-13|1985-05-21|The Salk Institute For Biological Studies|GRF Analogs III|

---

IL70530A|1983-01-13|1986-09-30|Salk Inst For Biological Studi|Synthetic peptides having growth hormone releasing factor activity and compositions containing them|

---

AU575843B2|1983-08-10|1988-08-11|The Administrators Of The Tulane Eductional Fund|Growth hormone releasing peptides|US4728726A|1982-10-04|1988-03-01|The Salk Institute For Biological Studies|GRF analogs IIIb|

---

US4732972A|1983-03-07|1988-03-22|Hoffmann-La Roche Inc.|Polypeptides having growth hormone releasing activity|

---

US4649131A|1984-09-24|1987-03-10|Hoffmann-La Roche Inc.|Growth hormone releasing factor analogs|

---

US4734399A|1985-08-06|1988-03-29|Hoffmann-La Roche Inc.|Growth hormone releasing factor analogs|

---

CA1271600A|1985-01-07|1990-07-10|David Howard Coy|Growth hormone-releasing peptides and method oftreating mammals therewith|

---

EP0193910A3|1985-03-06|1988-11-23|Sumitomo Pharmaceuticals Company, Limited|Synthesis of a derivative of grf and intermediate peptides|

---

US4689318A|1985-08-29|1987-08-25|The Salk Institute For Biological Studies|GRF analogs|

---

US4880778A|1986-05-12|1989-11-14|Eastman Kodak Company|Combinations having synergistic growth hormone releasing activity and methods for use thereof|

---

FR2599038B1|1986-05-26|1990-06-29|Sanofi Sa|PROCESS FOR THE PREPARATION OF NONACOSAPEPTIDES AND INTERMEDIATE PEPTIDES|

---

US5565606A|1986-10-21|1996-10-15|Hoechst Aktiengesellschaft|Synthesis of peptide aminoalkylamides and peptide hydrazides by the solid-phase method|

---

IL84758A|1987-01-13|1992-03-29|Salk Inst For Biological Studi|Peptides stimulating the release of pituitary growth hormone in fish and amphibians,and pharmaceutical compositions containing them|

---

US4843064A|1987-01-13|1989-06-27|The Salk Institute For Biological Studies|GRF analogs V|

---

US4914189A|1987-02-05|1990-04-03|The Adminstrators Of The Tulane Educational Fund|Synthetic GHRH analogs|

---

EP0289186A3|1987-04-23|1990-04-04|International Minerals And Chemical Corporation|Process for increasing the growth rate and enhancing the feed efficiency of meat producing livestock|

---

US5112808A|1987-05-11|1992-05-12|American Cyanamid Company|Alkylated hormone-releasing peptides and method of treatig mammals therewith|

---

IL86102A|1987-05-11|1994-04-12|Univ Tulane|Alkylated growth hormone-releasing peptides and use thereof|

---

US5002931A|1987-05-22|1991-03-26|The Salk Institute For Biological Studies|GRF analogs VII|

---

US4839344A|1987-06-12|1989-06-13|Eastman Kodak Company|Polypeptide compounds having growth hormone releasing activity|

---

US4801456A|1987-07-09|1989-01-31|International Minerals & Chemical Corp.|Growth hormone-releasing factor analogs|

---

USRE33699E|1987-07-09|1991-09-24|International Minerals & Chemical Corp.|Growth hormone-releasing factor analogs|

---

US4880777A|1987-09-01|1989-11-14|Eastman Kodak Company|Synthetic peptides having growth hormone releasing activity|

---

DE3850015T2|1987-09-18|1994-10-20|Hoffmann La Roche|Cyclic GRF analogues.|

---

DE3742633A1|1987-12-16|1989-06-29|Hoechst Ag|PEPTIDES WITH INFLUENCING EFFECT ON HYPOPHYSIS IN MAMMALS|

---

EP0400051B1|1988-01-28|1995-05-10|Polygen Holding Corporation|Polypeptide compounds having growth hormone releasing activity|

---

US5043322A|1988-07-22|1991-08-27|The Salk Institute For Biological Studies|Cyclic GRF analogs|

---

US5023322A|1988-08-31|1991-06-11|Mta Kutatas-Es Szervezetelemzo Intezete|Analogs of growth hormone releasing factorand a method for the preparation thereof|

---

US5756458A|1989-06-16|1998-05-26|Pharmacia & Upjohn Company|Stabilized potent GRF analogs|

---

US5716937A|1989-12-13|1998-02-10|The General Hospital Corporation|Method for treating cardiac malfunction|

---

AU656144B2|1990-06-29|1995-01-27|F. Hoffmann-La Roche Ag|Histidine substituted growth hormone releasing factor analogs|

---

DE69108192T2|1990-12-10|1995-07-20|Hoffmann La Roche|Process for the enzymatic production of GRFNH2.|

---

JPH05507939A|1991-04-09|1993-11-11|

---

ZA922746B|1991-04-26|1992-12-30|Lilly Co Eli|Superactive grf analogs|

---

US5246920A|1992-06-15|1993-09-21|University Of South Florida|Treatment of hyperprolactinemia|

---

US5811074A|1992-06-29|1998-09-22|University Of South Florida|Method of diagnosing pituitary dependent growth hormone deficiency|

---

GB9324691D0|1993-12-01|1994-01-19|Hafslund Nycomed As|Peptide compounds|

---

US5550212A|1993-12-17|1996-08-27|The Administrators Of The Tulane Educational Fund|Analogues of hGH-RHNH2 having antagonistic activity|

---

IT1285405B1|1995-06-06|1998-06-03|Alza Corp|MODIFICATION OF POLYPEPTIDIC DRUGS TO INCREASE THE FLOW BY ELECTRIC TRANSPORT.|

---

US7268113B2|2001-02-02|2007-09-11|Conjuchem Biotechnologies Inc.|Long lasting growth hormone releasing factor derivatives|

---

US20060128615A1|2002-09-18|2006-06-15|Pierrette Gaudreau|Ghrh analogues|

---

US20090088380A1|2007-07-12|2009-04-02|Pierrette Gaudreau|Ghrh analogs and therapeutic uses thereof|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/611,844|US4528190A|1983-10-25|1984-05-18|GRF Analogs IV|

---